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erythematosus (SLE) also it is one of the most important systems that can be affected in Juvenile
onset SLE (JOSLE). Early detection and evaluation of the extent and severity of pulmonary
involvement are quite critical for disease prognosis and patients management.
Aim of the work: To determine the frequency and type of pleuropulmonary involvement in
JOSLE using pulmonary function tests (PFTs) and multidetector CT (MDCT).
Patients and methods: Twenty ﬁve patients with JOSLE were evaluated for the detection of pleu-
ropulmonary affection in them. The evaluation included clinical, functional & radiological282847; fax: +20 552344552.
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164 E.E.-D. El-Shahawy et al.examination using MDCT as a recent & accurate modality for chest imaging. Based on clinical eval-
uation, patients were divided into two groups; group A (No = 16) and group B (No = 9), consist-
ing of those asymptomatic and symptomatic as regard pleuropulmonary symptoms, respectively.
Results: This study revealed that PFT abnormalities were detected in 60% of all studied JOSLE
patients while MDCT abnormalities were detected in 52% of them. 37.5% of the asymptomatic
patients had abnormal PFTs & 31.25% of them had abnormal ﬁndings on MDCT. There was sta-
tistically signiﬁcant difference between patients groups regarding SLEDAI, percentages of abnor-
mal PFTs, abnormalities in plain X-ray and MDCT. With the exception of forced expiratory
ﬂow at 25–75% of forced vital capacity (FEF25–75%), the study revealed statistically signiﬁcant
lower values of mean ± SD of all measured PFTs in group B compared to group A. The most fre-
quent MDCT ﬁndings in all studied patients were pleural effusion and pleural thickening in 16% of
all ﬁndings, also ground glass opacities found in 16% of all abnormalities suggesting early intersti-
tial lung disease.
Conclusion: Clinical assessment and PFTs revealed a signiﬁcant percentage of pleuropulmonary
involvement in JOSLE patients. MDCT can be helpful in diagnosing the pulmonary involvement in
asymptomatic JOSLE patients with normal chest X-ray and uncertain PFT.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Systemic lupus erythematosus (SLE) is a rare complex autoim-
mune disease with a multisystem involvement [1]. It character-
ized by inﬂammatory changes in connective tissues, blood
vessels, and serosal surfaces [2]. SLE may affect all compo-
nents of the respiratory system; it can affect the pleura, lung,
and respiratory muscles, all contributing to respiratory dys-
function [3].
Involvement of the respiratory system in SLE is relatively
common; between 40% and 57% of patients with SLE may
have symptoms of dyspnea and poor exercise tolerance [4].
These symptoms may arise from primary pulmonary dysfunc-
tion, a complication secondary to infection, or from a disease
process in another system as renal failure leading to pulmon-
ary edema [4]. The pleuropulmonary manifestations of SLE
range in severity from the minor pleuritic pain of serositis to
the life threatening consequences of pulmonary haemorrhage.
Many of the abnormalities have non-speciﬁc presentations and
require extensive work up to determine the aetiologies [5].
Finding the true prevalence of lung involvement with SLE
is complicated by the high rates of pulmonary infections [6].
Pleuritis occurs in 17–60% of patients at some point in the
course of the disease [7]. Lung involvement occurring in 80%
of SLE patients at autopsy and chart review from past reports
is now thought to be largely a result of infection and not di-
rectly SLE-induced [8].
Although pulmonary involvement is relatively frequent in
adult patients; it has been rarely reported in children with
SLE. It may be an initial and/or life-threatening complication
of jeuvenile SLE [9,10], but neither clinical ﬁndings nor roent-
genogram were speciﬁc [11].
The most commonly used noninvasive methods for the
study of interstitial lung disease are pulmonary function tests
(PFTs) and high-resolution computed tomography (HRCT)
[12]. However, different HRCT series have demonstrated a
higher rate of ILD features (about one third of SLE patients),
suggesting that subclinical lung disease is common [13].
The aim of this study was to determine the frequency and
type of pleuropulmonary involvement in juvenile onset SLE
(JOSLE) using PFTs and multidetector CT (MDCT).2. Patients and methods
2.1. Patients
Twenty ﬁve patients with juvenile onset systemic lupus erythe-
matosus (JOSLE) were included in this study. All fulﬁlled the
1997 updated American College of Rheumatology criteria for
SLE [14]. All the patients had the disease at or before the age
of 16 years. However at inclusion in the study, their ages ran-
ged from (10–18 years) and the disease duration ranged from
(3.3–8.4 years).
They were recruited from inpatient and outpatient clinics of
Rheumatology & Rehabilitation, Chest, and Pediatric depart-
ments of Zagazig University Hospitals from October 2008 to
August 2010. Patients were unable to undergo CT technique
and those with pulmonary manifestations secondary to ad-
vanced cardiac disease or renal failure were excluded from
the study. All patients received prednisone; 13 were taking aza-
thioprine, 6 patients were receiving cyclophosphamide and se-
ven were receiving hydroxychloroquine. An informed written
consent was obtained from patients’ guardians.
All patients were subjected to full assessment including his-
tory taking with stress on any symptoms of pleuropulmonary
involvement as cough, expectoration, chest pain and wheeze,
dyspnea and hemoptysis. Clinical examination was done with
stress on local chest examination. Based on pleuropulmonary
manifestations, patients were divided into two groups; group
A (No = 16) and group B (No = 9), consisting of those asymp-
tomatic and symptomatic patients respectively. Assessment of
disease activity was done through SLE Disease Activity Index
(SLEDAI) described by Bombardier et al. [15].
2.2. Pulmonary function tests
They were performed using (ZAN 100 Flow Handy II) pul-
monary function apparatus. Pulmonary function testing was
done according to Grippi and Tino [16]. Observed values were
compared with those predicted for age, sex, and height for
each individual.
The following parameters were assessed; forced vital capac-
ity (FVC) and FVC% of predicted. Forced expiratory volume
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FEV1/FVC was measured. Maximum voluntary ventilation
(MVV) (liter/min) & MVV% of predicated. Lastly forced expi-
ratory ﬂow at 25–75% of forced vital capacity (FEF25–75%)
was calculated.
Every parameter obtained by spirometric pulmonary func-
tion testing was expressed as a percentage (%) from predicted
values, and depending on the results patients were categorized
as follow; normal pulmonary functions 80-100% of predicated,
obstructive if FEV1/FVC < 70%, restrictive if FVC< 80% of
predicted and FEV1/FVC > 70%, combined obstructive and
restrictive if FVC < 80% of predicted and FEV1/
FVC< 70% while small airway dysfunction when FEF25–
75% is less than 65% of predicted.
2.3. Arterial blood gases analysis (ABG)
Hypoxemia was diagnosed when PaO2 is less than 70 mm Hg
& Hypocarbia was diagnosed when PaCO2 is less than
33 mm Hg [17].
2.4. Laboratory investigations
Routine laboratory tests: Complete blood count (CBC), eryth-
rocyte sedimentation rate (ESR), antinuclear antibody (ANA)
was done with the indirect immunoﬂorescence technique using
(Hep-2 substrate, IMMCO Diagnostics, Inc., USA, comple-
ment C3 (ProSpec-Dade Behring), anti-dsDNA Ab was also
determined by EIA (the Binding Site, Birmingham, U.K).
Sputum & induced sputum examination by Gram stain and
Ziehl Nielsen stain. Sputum induction was performed accord-
ing to Mandell et al. [18] by inhalation of nebulized hypertonic
saline (20 mL of 3% hypertonic saline for 30 min).
2.5. Radiological examination
2.5.1. Plain chest X-ray (CXR)Postero–anterior & lateral
views.
2.5.2. Multidetector CT (MDCT) examination and evaluation
Chest scanning was done using 64 multidetectors CT scanner
(GE lightspeed-VCT). All patients underwent cranio-caudal
scanning in a supine position and at end-inspiratory suspension
during a single breath hold, thin section scans were obtained.
Acquisition parameters of tube voltage, tube current and slice
thickness were 120 kV potential (kVp), 130–150 mAs and
1 mm respectively.Table 1 Demographic, clinical and radiological features of both gr
Variables Group A No. = 16
Age (years) (mean ± SD) 14.0 ± 3.2
Sex (female/male) No 13/3
Disease duration (years) 5.21 ± 1.4
SLEDAI (mean ± SD) 10.62 ± 3.87
Abnormal PFTs (No,%) 6 (37.5%)
Abnormal plain X-ray (No,%) 1 (6.25%)
Abnormal MDCT (No,%) 5 (31.25%)
JOSLE= juvenile onset SLE, Group A= asymptomatic patients, Group
* Signiﬁcant when compared Group A versus B.I.V. contrast was given to the clinically suspect case of hav-
ing pulmonary embolism after laboratory estimation of blood
urea and creatinine by injecting 100 mm of non ionic contrast
using automatic injector at a rate of 3–4 ml/s and scanning be-
gan 20–25 s after start of injection.
The axial raw data acquired was transferred to the advan-
tage windows work station (AdvantageWindow, Volume share
4) where multiplanar reconstruction (MPR) software was used
to reconstruct coronal and sagittal images at mediastinal win-
dow setting.
Statistics: The collected data were statistically analyzed
using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA), com-
parison between group means was done using student’s t-test
while chi-squared test was used for qualitative data. The signif-
icance level was considered at P< 0.05.
3. Results
3.1. Data of all studied juvenile onset SLE patients
This study included 25 patients with juvenile onset SLE, 21
females and 4 males, their mean age was 14.3 ± 3.13 years, ran-
ged from 10 to 18 years and mean disease duration was
5.6 ± 1.62 years, ranged from 3.3 to 8.4 years. The mean of
SLEDAI of all studied patients was 12.04 ± 4.18. Among all
studied patients, frequency of chest symptoms presented in 9
patients (group B) in form of 7 symptoms of dyspnea, 5 of
expectoration, another 4 symptoms with chest pain while cough
and chest wheeze each was detected three times, and hemopty-
sis presented once only. Abnormal PFTs were detected in 15
(60%) of total JOSLE patients while abnormalities in plain
X-ray were in 7 (28%) patients however 13 (52%) out of the
25 studied patients had abnormal MDCT ﬁndings.
3.2. Comparison between asymptomatic and symptomatic
patients
Table 1 illustrates demographic, clinical and radiological fea-
tures of both groups of patients. There was none signiﬁcant dif-
ference between group A (asymptomatic) and group B
(symptomatic) as regard age, sex and disease duration. How-
ever there was signiﬁcant difference between both of them as re-
gard mean of SLEDAI (P< 0.001), percentage of abnormal
PFTs (P= 0.002) and abnormalities in plain X-ray (P=
0.002) and MDCT (P< 0.01). Abnormal MDCT detected in
31.25% of the asymptomatic patients.oups of JOSLE patients.
Group B No. = 9 P
15.0 ± 2.91 0.45
8/1 1.0
6.3 ± 1.76 0.09
14.65 ± 3.74 0.02*
9 (100%) 0.002*
6 (66.6%) 0.002*
8 (88.9%) 0.01*
B = symptomatic patients, SLEDAI = SLE Disease Activity Index.
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dysfunction among all studied patients
There was a statistically signiﬁcant difference between symp-
tomatic and asymptomatic patients regarding mean ± SD of
FVC% (P< 0.001), FEV1% (P< 0.001), FEV1/FVC (P<
0.01) and MVV% of predicted values (P< 0.01) (Table 2.).
Table 3 shows that the most frequent ventilatory dysfunc-
tion in the studied JOSLE patients was restrictive pattern in
24% of them and the least was the small airway dysfunction
in 8% of patients only. There was statistically signiﬁcant dif-
ference between both patients’ groups regarding total ventila-
tory dysfunction (P= 0.02).
3.4. Arterial blood gases analysis (ABG) in both patients’
groups
All patients in group A (asymptomatic) had normal ABG
while in group B (symptomatic), 2 patients only had normal
ABG (22.2%), 3 patients had hypoxemia (33.35%) and four
had hypocarbia (44.4%). There was highly signiﬁcant differ-
ence between symptomatic and asymptomatic groups as
regards results of ABG analysis (P< 0.001).
3.5. Findings of plain X-ray and multidetector CT among all
studied patients
As regard abnormalities in plain X-ray, one patient only in
groups A had pleural thickening, while 6 patients in groups
B had abnormalities in the form of consoliditions, nodular
areas and pleural effusion.
Multidetector CT examination of JOSLE patients with and
without symptoms demonstrated in Table 4 where the most
frequent MDCT ﬁndings in all studied patients were pleuralTable 2 Mean pulmonary function tests in both groups of JOSLE
Pulmonary function tests Group A No. = 16
FVC% 77.6 ± 7.4
FEV1% 76.9 ± 6.6
FEV1/ FVC% 76.6 ± 8.3
FEF25–75% 75.5 ± 5.1
MVV% 78.3 ± 12.4
JOSLE= juvenile onset SLE, Group A= asymptomatic patients, Gro
predicted, FEV1%= Forced expiratory volume in 1 s of predicted,
75% = forced expiratory ﬂow at 25–75% of forced vital capacity. Group
* Signiﬁcant when compared Group A versus B.
Table 3 Frequency of ventilatory dysfunction among all studied pa
Ventilator dysfunction Group A No. = 16
No %
Obstructive dysfunction 1 6.25
Restrictive dysfunction 2 12.5
Combined obstructive and restrictive 2 12.5
Small airway dysfunction 1 6.25
Total 6 37.5
Group A= asymptomatic patients, Group B = symptomatic patients.
* Signiﬁcant when compared Group A versus B.effusion and pleural thickening in 16% of all ﬁndings, also
ground glass opacities found in 16% of all abnormalities sug-
gesting early interstitial lung disease. The least frequent ﬁnd-
ings were septal lines, honeycoombing and pulmonary artery
ﬁlling defect, each was detected in 4% only (Figs. 1 and 2).
There was highly signiﬁcant difference between symptom-
atic and asymptomatic patients regarding total abnormal CT
ﬁndings being higher in symptomatic group, P< 0.001.
3.6. Final diagnosis of pleuropulmonary manifestations in
JOSLE patients
It was found that the most frequent pleuropulmonary manifes-
tations were pleural effusion and thickening in 16% of JOSLE
patients, also interstitial lung disease was detected in 16% of
studied patients. Community acquired pneumonia was de-
tected in 12% of them. Bronchiectasis was found in one patient
also acute pulmonary embolism was diagnosed in one patient
only where anticardiolipin antibodies was positive in this pa-
tient. The overall frequency of pleuropulmonary affection
(both symptomatic and asymptomatic) was 52% in all studied
JOSLE patients.
4. Discussion
The pleuropulmonary complications associated with the colla-
gen vascular diseases are frequent occurrences; all the elements
of the respiratory system may be affected either separately or
in combination [19]. Early detection and evaluation of the ex-
tent and severity of pulmonary involvement is quite critical for
collagen vascular disease prognosis and patient management
[20].
This study revealed a statistically signiﬁcant difference be-
tween symptomatic & asymptomatic patients regarding SLE-patients.
Group B No. = 9 P
61.4 ± 9.4 0.001*
60.3 ± 8.6 0.001*
65.5 ± 10.2 0.01*
60.1 ± 14.1 0.12
66.7 ± 6.2 0.01*
up B = symptomatic patients, FVC%= Forced vital capacity of
MVV%=Maximum voluntary ventilation of predicated, FEF25–
A = asymptomatic patients, Group B = symptomatic patients.
tients.
Group B No. = 9 Total No.= 25 P
No % No %
2 22.2 3 12 0.5
4 44.4 6 24 0.14
2 22.2 4 16 0.60
1 11.1 2 8 1.0
9 100 15 60 0.02*
Table 4 Comparison between patients’ groups as regards ﬁndings of multidetector CT.
Findings Group A No.= 16 Group B No. = 9 Total No. = 25 P
No % No % No %
Ground glass 1 6.25 3 33.3 4 16 0.11
Consolidation 0 0 3 33.3 3 12 0.03*
Nodular areas of high attenuation 0 0 2 22.2 2 8 0.12
Septal lines 1 6.25 0 0 1 4 0.36
No septal lines 1 6.25 2 22.2 3 12 0.53
Honeycoombing 0 0 1 11.1 1 4 0.36
Pleural eﬀusion and thickening 2 12.5 2 22.2 4 16 0.60
Pulmonary artery ﬁlling defect 0 0 1 11.1 1 4 0.36
Group A = asymptomatic patients, Group B = symptomatic patients.
* Signiﬁcant when compared Group A versus B.
Figure 1 Female patient 16 years old suffered from dry cough and dyspnea, her PFTs shows a restrictive pattern, (A) axial CT scan
shows reticular perihilar opacities in both lungs, (B) Sagittal MPR image shows the craniocaudal extent of the reticular opacities.
Figure 2 Female patient 14 years old suffered from chest pain and grade II dyspnea, her PFTs showed a restrictive pattern, (A) plain
chest shows accentuated lung markings, (B) axial CT scan of demonstrates ground-glass attenuation of both lungs, (C) coronal MPR
image shows basal tiny cystic changes.
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2001, Al-Abbad et al. stated that various percentages of abnor-
mal PFTs were recorded by several investigators; the variation
could be attributed to different clinical data of the studied
groups as regard age of onset, duration of illness and whether
they have symptomatic chest problems [21].
Authors explained that, in SLE patients without clinical
evidence of respiratory involvement, pulmonary function
abnormalities have been reported in a number of studies of
childhood onset SLE, which suggests the presence of subclini-
cal disease [22]. They have found that PFT results were im-
paired in 37% of the patients & they concluded that lung
function was moderately impaired while the frequency ofpulmonary parenchymal involvement was low in patients with
childhood-onset SLE. Grippi & Tino stated that ventilatory
pulmonary function tests are effort dependent and those pa-
tients frequently have poor respiratory effort, anemia and
physical unﬁtness [19]. Several studies [23,13] reported abnor-
mal HRCT in asymptomatic SLE patients detected in 70%
and 72% respectively of those patients. These studies con-
cluded that screening of patients with connective tissue disease
for pulmonary abnormalities is very important even in asymp-
tomatic patients.
This study revealed that restrictive ventilatory dysfunction
was much frequent than obstructive ventilatory dysfunction.
The least observed ventilatory dysfunction was small airway
168 E.E.-D. El-Shahawy et al.dysfunction in only 8% of patients. There was statistically sig-
niﬁcant difference between symptomatic and asymptomatic
patients regarding overall pulmonary function abnormalities.
This is in agreement with Kakati et al. [24] who observed that
28.95% of patients with SLE had abnormal PFT results and
the most frequent ventilatory dysfunction was restrictive pat-
tern in 26.3% of patients. Obstructive dysfunction in our pa-
tients can be attributed to the ﬁnal diagnosis in those
patients of bronchiectasis, acute pulmonary embolism and
pneumonia with excessive airway secretions or bronchospasm.
Small airway dysfunction can be attributed to early interstitial
lung disease in those patients.
Restrictive dysfunction can be attributed to the ﬁnal diag-
nosis of pleural effusion and pleural thickening and interstitial
lung disease. Combined obstructive and restrictive dysfunction
can also be a manifestation of ILD and bronchiectasis.
Researchers explained that the restrictive pattern of pulmon-
ary function can be attributed to diaphragmatic myopathy
and this may occur in 25% of patients with SLE [19]. One
study performed on 64 children with juvenile SLE for detec-
tion of pleuropulmonary manifestations in them. Infectious
pneumonia was found in 38%, pleuritis in 33%, pulmonary
vasculitis in 11% and acute lupus pneumonitis, chronic inter-
stitial pneumonia and pulmonary embolism, each one in
5.5% of patients [25].
In the present study we usedMDCT examination of the tho-
rax as a rapid and accurate technique. MDCT scanners now use
multiple beams, so that 4–64 images are created simultaneously
and at amuch faster rate thanwhen a single detector is used [26].
The most frequent MDCT ﬁndings in the studied JOSLE
patients were pleural effusion and pleural thickening in 16%
of all ﬁndings and ground glass opacities suggestive of early
interstitial lung disease in another 16%. Lalani et al. men-
tioned that pleural effusions are the most common manifesta-
tion of SLE in the respiratory system and are bilateral in
approximately 50% of patients [4].
Evidence of pulmonary consolidation during MDCT exam-
ination of JOSLE patients was present in 12% of patients. This
is compatible with the ﬁnal diagnosis of community acquired
pneumonia in the same patients under immunosuppression.
Also, nodular areas of high attenuation in 8% of patients, sep-
tal lines in 4% and non septal lines in 12% of patients, all are
suggestive of irreversible pulmonary ﬁbrosis and may be sequel
of infectious pneumonia or acute lupus pneumonitis. Cosgrove
and Schwarz emphasized that infectious pneumonia represents
the most common cause of pulmonary disease in SLE patients
[19]. Researchers concluded that common HRCT ﬁndings are
interstitial thickening or thickened interlobular septa, paren-
chymal bands and ground glass opaciﬁcation and most of
these features suggest ILD [24].
In the present study, honeycoombing was detected on muti-
detector CT examination of JOSLE in 4%, this is compatible
with the ﬁnal diagnosis of bronchiectasis in the same patient.
This is in agreement with Kakati et al. who reported bronchi-
ectasis in 2.8% of SLE patients on HRCT thoracic examina-
tion [24].
One of the observed ﬁndings of JOSLE patients is pulmon-
ary artery ﬁlling defect in 4% on multidetector CT examina-
tion. This is compatible with the ﬁnal diagnosis of acute
pulmonary embolism in the same patient. Acute pulmonary
embolism was diagnosed on the basis of history of acute dysp-
nea together with the ﬁnding of tachypnea, hypoxemia andhypocarbia on ABG analysis; this was conﬁrmed on MDCT
examination with dye. One study stated that the occurrence
of pulmonary thromboembolic disease correlates with the
presence in the serum of antiphospholipid antibodies [19].
In conclusion clinical assessment and PFTs revealed a sig-
niﬁcant percentage of pleuropulmonary involvement in JOSLE
patients. MDCT can be helpful in diagnosing the pulmonary
involvement in asymptomatic JOSLE patients with normal
chest X-ray and uncertain PFT. Assessment of diffusion
capacity of carbon monoxide is recommended for further
studying of pluropulmonary involvement in SLE. A wider
study on a bigger number of patients may investigate the cor-
relations between the detected abnormalities of PFTs and
MDCT, and the disease manifestations and drugs used by
the involved patients.
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